Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Sep 13 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing the receipt of final approval from the USFDA for Lenalidomide Capsules in multiple strengths. The approval includes final permissions for several strengths and tentative approvals for others, indicating the company's expansion in oncology therapies. The drug is intended for treating various cancers and certain blood disorders, and will be manufactured in Ahmedabad, India. The company aims to enhance access to affordable medication in the US market with this approval.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases